Search results for "MAV"

showing 10 items of 335 documents

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared wit…

2011

BACKGROUND: The human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine is immunogenic, has a clinically acceptable safety profile, and prevents incident and persistent HPV-16/18 infection and cervical precancerous lesions. This study (NCT00552279) evaluated the vaccine when administered according to an alternative dosing schedule (0-1-12 months) compared with the standard dosing schedule (0-1-6 months). METHODS: The study was of randomized open design and was conducted at multiple centers in Europe. Healthy women aged 15 to 25 years were randomized (1:1) to receive HPV-16/18 vaccine according to the standard schedule at months 0, 1, and 6 (n = 401) or an alternative schedule at months 0, …

AdultMicrobiology (medical)medicine.medical_specialtyScheduleAdolescentImmunization SecondaryEnzyme-Linked Immunosorbent AssayAntibodies Virallaw.inventionYoung AdultAdjuvants ImmunologicRandomized controlled triallawInternal medicinemedicineHumansPapillomavirus VaccinesDosingHuman papillomavirusYoung adultbusiness.industryImmunogenicityhuman papillomavirus human papillomavirus vaccines adolescent immunology alternative dosing scheduleVaccinationvirus diseasesSettore MED/40 - Ginecologia E Ostetriciafemale genital diseases and pregnancy complicationsEuropeSafety profileInfectious DiseasesImmunizationPediatrics Perinatology and Child HealthImmunologyFemalebusiness
researchProduct

Human papillomavirus antibody responses among patients with incident cervical carcinoma

1997

The human papillomavirus (HPV) is recognized as a major cause of cervical cancer precursor lesions. HPV serology is a key method in the continuing elucidation of the importance of HPV exposure for cancer development and in predicting HPV-associated diseases. To extend previous HPV serological studies on cervical cancer, serum samples from a consecutive series of 216 women with incident untreated cervical carcinoma and 243 age- and sex-matched healthy blood donors were evaluated for the presence of antibodies against HPV capsids, a marker of past or present HPV exposure, as well as against several cervical cancer-associated defined HPV epitopes. Among the capsid antibody responses, HPV type …

AdultMolecular Sequence DataUterine Cervical NeoplasmsAntibodies ViralKlinikai orvostudományokEpitopeSerologyEpitopesCapsidRisk FactorsVirologyCarcinomamedicineHumansAmino Acid SequenceRisk factorAntigens ViralPapillomaviridaeAgedAged 80 and overCervical cancerbiologybusiness.industryPapillomavirus Infectionsvirus diseasesOrvostudományokMiddle Agedmedicine.diseaseVirologyfemale genital diseases and pregnancy complicationsTumor Virus InfectionsInfectious DiseasesCase-Control StudiesImmunologybiology.proteinFemaleHuman Papillomavirus AntibodyViral diseaseAntibodybusiness
researchProduct

Telomere length in leukocytes and cervical smears of women with high-risk human papillomavirus (HR HPV) infection

2019

Objective: Persistent high-risk HPV (HR HPV) infection leads to the development of squamous intraepithelial lesions, which in turn may progress to cervical cancer. Telomere elongation or shortening may indicate a carcinogenesis process. In the present study, we analyzed telomere length from blood and cervical smears of women without and with high-risk HPV infection. Materials and methods: Telomere length was quantified by real-time PCR in blood and cervical smears from 48 women with high-risk HPV infection and HGSIL or LGSIL, 29 women HR-HPV positive without SIL, and 11 HPV-negative women. Results: No correlation was found between age and telomere length in blood and cervical smears. Women …

AdultOncologyHuman papillomavirusmedicine.medical_specialtyUterine Cervical NeoplasmsCervix Uterimedicine.disease_causelcsh:Gynecology and obstetricsRisk Assessment03 medical and health sciences0302 clinical medicineInternal medicineLeukocytesHumansMedicineHuman papillomavirusPapillomaviridaelcsh:RG1-991Early Detection of CancerVaginal SmearsCervical cancer030219 obstetrics & reproductive medicinebusiness.industryPapillomavirus InfectionsHPV infectionvirus diseasesObstetrics and GynecologyCervical cellsLeukocyteTelomeremedicine.diseaseCervical smearsfemale genital diseases and pregnancy complicationsTelomereCervical smearCase-Control StudiesFemalebusinessCarcinogenesisTelomere elongationPapanicolaou TestTaiwanese Journal of Obstetrics and Gynecology
researchProduct

Proliferative verrucous vs conventional leukoplakia: no significantly increased risk of HPV infection

2004

Proliferative verrucous leukoplakia (PVL) is a very aggressive form of oral leukoplakia (OL) with high morbidity and mortality rates, hypothesised to be linked to HPV infection. This study aimed to determine the presence of HPV DNA in PVL in comparison with OL, and in relation to social-demographical variables (age, gender, smoking and drinking habits) in an Italian multi-centric hospital-based study. The study group consisted of 58 cases of PVL and 90 cases of OL as controls (47 homogeneous (H) and 43 non-homogeneous (non-H) form), both recruited from four Italian cohorts. HPV DNA was identified in exfoliated mucosal cells by nested PCR (nPCR) with MY09/MY11 and GP5+/GP6+ primer pairs and …

AdultOralMaleCancer Researchmedicine.medical_specialtyGenotypeGastroenterologyVirusVerrucousRisk FactorsInternal medicineGenotypemedicineCarcinomaHumansCarcinoma VerrucousViralPapillomaviridaeRisk factorPapillomaviridaeLeukoplakiaAdult; Carcinoma; Verrucous; DNA; Viral; Female; Genotype; Humans; Leukoplakia; Oral; Male; Middle Aged; Papillomaviridae; Papillomavirus Infections; Risk Factors; SmokingbiologyCarcinomaPapillomavirus InfectionsSmokingHPV infectionvirus diseasesDNAMiddle Agedmedicine.diseasebiology.organism_classificationVirologyfemale genital diseases and pregnancy complicationsOncologyDNA ViralFemaleOral SurgeryLeukoplakia OralNested polymerase chain reactionLeukoplakia
researchProduct

Abnormal Immunoexpression of Cell Adhesion Molecules (CAMs) in Cervical Cancer

2010

Artículo publicado en: International Journal of Surgical Pathology published online 18 July 2010 The purpose of this study was to examine the immunoexpression of cell adhesion molecules (CAMs) E-cadherin, CD44s, and CD44v3 in cervical cancer and compare it with that in benign exo-endocervical tissue. In all, 81 cervical cancer biopsy specimens and 22 benign controls were included. Primary monoclonal antibodies NHC-38, F10-44-2, and 3G5 for E-cadherin, CD44s, and CD44v3 were used, respectively. Statistical significance was evaluated by the ?2 test. Antigen expression was significantly different in cervical cancer specimens compared with controls, showing marked decrease in membrane expressio…

AdultPathologymedicine.medical_specialtyUterine Cervical NeoplasmsAdenocarcinomaAlphapapillomavirusBiologyPathology and Forensic MedicineImmunoenzyme TechniquesBiopsyBiomarkers TumormedicineHumansDNA Probes HPVCell adhesionAgedCervical cancermedicine.diagnostic_testCadherinCell adhesion moleculeCD44v3Papillomavirus InfectionsE-cadherinCancerArtículosMiddle AgedFacultad de Farmacia y BioanálisisCadherinsmedicine.diseaseImmunohistochemistryHyaluronan ReceptorsTissue Array AnalysisDNA ViralCervical cancerCD44sImmunohistochemistryFemaleSurgeryAnatomyImmunostainingInternational Journal of Surgical Pathology
researchProduct

Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer

1997

Background: Major risk factors for invasive cervical cancer include infection with human papillomavirus (HPV), infection with other sexually transmitted pathogens (e.g., Chlamydia trachomatis), and smoking. Since exposures to these risk factors can be related, the contribution of any single factor to cervical carcinogenesis has been difficult to assess. We conducted a prospective study to define the role of HPV infection in cervical carcinogenesis, with invasive cancer as an end point. Methods: A nested case‐control study within a joint cohort of 700 000 Nordic subjects was performed. The 182 women who developed invasive cervical cancer during a mean follow-up of 5 years were matched with 5…

AdultRiskCancer Researchmedicine.medical_specialtyRadioimmunoassaySexually Transmitted DiseasesUterine Cervical NeoplasmsAdenocarcinomamedicine.disease_causeSerology03 medical and health sciences0302 clinical medicineRisk FactorsSeroepidemiologic StudiesInternal medicinePrevalencemedicineHumansNeoplasm InvasivenessProspective Studies030212 general & internal medicinePapillomaviridaeRisk factorPapillomaviridaeGynecologyCervical cancerbiologybusiness.industryIncidencePapillomavirus InfectionsHPV infectionCancerMiddle Agedbiology.organism_classificationmedicine.disease3. Good healthTumor Virus InfectionsOncologyCase-Control Studies030220 oncology & carcinogenesisRelative riskCarcinoma Squamous CellFemalebusinessChlamydia trachomatis
researchProduct

Impact of a new carrageenan-based vaginal microbicide in a female population with genital HPV-infection: First experimental results

2019

OBJECTIVE: The objective of this study was to assess safety, satisfaction, and anti- viral effect of a new carrageenan-based vaginal microbicide in a population of fertile female patients with genital human papillomavirus (HPV) infection. PATIENTS AND METHODS: Forty healthy and sexually active women aged 18-45 years with genital HPV infection were enrolled. Each subject was treated with a gel formulated with 0.02% carrageenan and Propionibacterium extract (CGP) (Carvir, Depofarma SpA, Mogliano Veneto, Treviso, Italy). The subjects were evaluated at baseline, after the I cycle of therapy and after the II cycle. At final status, treatment acceptability and satisfaction were evaluated using a …

AdultSettore MED/07 - Microbiologia E Microbiologia ClinicaHPVAdolescentSocio-culturaleMicrobicideCarrageenanCarrageenan Papillomavirus Microbicide Female population HPV.Young AdultAnti-Infective AgentsChondrusHumansProspective StudiesCarrageenan Papillomavirus Microbicide Female population HPVPapillomaviridaeFemale populationPapillomavirus InfectionsMiddle AgedPapillomavirusSeaweedAdministration IntravaginalTreatment OutcomeColposcopyPatient SatisfactionCase-Control StudiesDNA ViralVaginaVaginal Creams Foams and JelliesFemaleFollow-Up Studies
researchProduct

Immunohistochemical expression of ubiquitin and telomerase in cervical cancer

2009

Artículo publicado en: Virchows Arch (2009) 455:235–243. DOI 10.1007/s00428-009-0818-7 Ubiquitin and telomerase immunohistochemical expression patterns in cervical cancer were compared with normal cervical tissue samples. Eighty-one cervical cancer cases and 22 normal exo–endocervical tissue were examined with polyclonal antibody for ubiquitin and 44G12 clone for telomerase using tissue microarrays. The results were interpreted using a semiquantitative scale The average age of patients was 50.67 years. The most frequent histological types were moderately differentiated epidermoid carcinoma (43.5%), according to the degree of differentiation, and endocervical adenocarcinoma (42.1%). Immunohi…

AdultTelomerasePathologymedicine.medical_specialtyBiologíaClone (cell biology)Uterine Cervical NeoplasmsCervix UteriBiologyPathology and Forensic MedicineUbiquitinBiomarkers TumormedicineHumansPapillomaviridaeTelomeraseMolecular BiologyAgedCervical cancerTissue microarrayUbiquitinCancerArtículosCell BiologyGeneral MedicineMiddle AgedFacultad de Farmacia y Bioanálisismedicine.diseaseImmunohistochemistryImmunohistochemical expressionEpidermoid carcinomaTissue Array AnalysisCervical cancerbiology.proteinImmunohistochemistryFemaleVirchows Archiv
researchProduct

Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 y…

2009

This observer-blind study compared the prophylactic human papillomavirus (HPV) vaccines, Cervarix (GlaxoSmithKline) and Gardasil (Merck), by assessing immunogenicity and safety through one month after completion of the three-dose vaccination course. Women (n = 1106) were stratified by age (18-26, 27-35, 36-45 years) and randomized (1:1) to receive Cervarix (Months 0, 1, 6) or Gardasil (Months 0, 2, 6). At Month 7 after first vaccination, all women in the according-to-protocol cohort who were seronegative/DNA negative before vaccination for the HPV type analyzed had seroconverted for HPV-16 and HPV-18 serum neutralizing antibodies, as measured by pseudovirion-based neutralization assay (PBNA…

Adultmedicine.medical_specialtyAdolescentImmunologyAntibodies ViralCancer VaccinesSerologyYoung AdultHuman Papillomavirus Recombinant Vaccine Quadrivalent Types 6 11 16 18Neutralization TestsInternal medicinemedicineHumansPapillomavirus VaccinesGeneral Pharmacology Toxicology and PharmaceuticsNeutralizing antibodyPapillomaviridaeCervical cancerbiologybusiness.industryImmunogenicityGardasilPapillomavirus InfectionsMiddle Agedmedicine.diseaseAntibodies NeutralizingVaccinationImmunologyCohortbiology.proteinFemaleCervarixbusinessmedicine.drugHuman Vaccines
researchProduct

Prevalence of human papillomavirus types in women screened by cytology in Germany.

2007

Incidence and mortality rates of cervical cancer are higher in Germany than in other Western European countries. Type-specific human papillomavirus (HPV) distribution was investigated for the first time in Germany in an epidemiological study including 8,101 women. Women above the age of 30 years, self-referring for cervical cancer screening, were enrolled in two study centers in Hannover (Northern Germany) and Tubingen (Southern Germany). Participants were screened by the Pap smear and the hybrid capture 2 (HC2) test using the high-risk probe. All samples that were positive by the HC2 test were genotyped using the prototype PGMY09/11 PCR line blot assay. Most women in the study population h…

Adultmedicine.medical_specialtyCytodiagnosisUterine Cervical NeoplasmsCervical intraepithelial neoplasiaCohort StudiesSpecies SpecificityRisk FactorsVirologyGermanyEpidemiologymedicinePrevalenceHumansPapillomaviridaePapillomaviridaeGynecologyCervical cancerbiologybusiness.industryObstetricsMortality rateIncidence (epidemiology)Papillomavirus InfectionsMiddle Agedbiology.organism_classificationmedicine.diseaseVirologyVaccinationInfectious DiseasesPopulation studyFemalebusinessCarcinoma in SituJournal of medical virology
researchProduct